BRAF and cancer: These FDA-approved inhibitors do not address the clinical needs of non-BRAFV600 mutants; non-BRAFV600 mutants encompass roughly 50% of BRAF mutants in non-small cell lung cancer patients and 30% of all cancer patients contain an upstream RAS mutation (17).